Dyne Therapeutics Inc’s filing revealed that its Chief Scientific Officer Beskrovnaya Oxana unloaded Company’s shares for reported $65632.0 on Dec 11 ’24. In the deal valued at $28.12 per share,2,334 shares were sold. As a result of this transaction, Beskrovnaya Oxana now holds 201,685 shares worth roughly $4.99 million.
Then, Scalzo Richard William sold 1,455 shares, generating $40,915 in total proceeds. Upon selling the shares at $28.12, the SVP, Head of Finance & Admin. now owns 127,078 shares.
Before that, HIGH SUSANNA GATTI bought 5,270 shares. Dyne Therapeutics Inc shares valued at $149,299 were divested by the Officer at a price of $28.33 per share.
Robert W. Baird initiated its Dyne Therapeutics Inc [DYN] rating to an Outperform in a research note published on December 13, 2024; the price target was $46. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late November with a ‘”an Outperform”‘ rating. JP Morgan also remained covering DYN and has decreased its forecast on October 24, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. Chardan Capital Markets maintained its rating on May 21, 2024. It rated DYN as “a Buy”.
Price Performance Review of DYN
On Friday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock fall -2.75% to $24.76. Over the last five days, the stock has gained 1.19%. Dyne Therapeutics Inc shares have risen nearly 5.09% since the year began. Nevertheless, the stocks have risen 67.64% over the past one year. While a 52-week high of $47.45 was reached on 01/02/25, a 52-week low of $12.33 was recorded on 01/02/25. SMA at 50 days reached $28.09, while 200 days put it at $32.58.
Levels Of Support And Resistance For DYN Stock
The 24-hour chart illustrates a support level at 23.95, which if violated will result in even more drops to 23.13. On the upside, there is a resistance level at 25.88. A further resistance level may holdings at 26.99. The Relative Strength Index (RSI) on the 14-day chart is 42.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 53.02%. Stochastics %K at 36.23% indicates the stock is a holding.
How much short interest is there in Dyne Therapeutics Inc?
A steep rise in short interest was recorded in Dyne Therapeutics Inc stocks on 2024-12-13, growing by 0.25 million shares to a total of 10.4 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 10.15 million shares. There was a rise of 2.38%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 30, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
